Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07459647 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 42 → 45 locations
    • Eligibility criteria expanded, about 14 words
  2. Study sites: 41 to 42v4
  3. Trial sites expanded: 5 → 41 locationsv3
  4. Recruitment opened
    • Trial sites expanded: 0 → 5 locations
    • Start date changed from estimate of Mar 2026 to Mar 31, 2026
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).
Trial Details
NCT Number NCT07459647
Lead Sponsor MapLight Therapeutics
Conditions
(from sponsor)		 Schizophrenia
Related terms Brain Diseases, Central Nervous System Diseases, Mental Disorders, Nervous System Diseases, Psychotic Disorders, Schizophrenia
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov